Cogstate Joins New Collaborative of Global Healthcare Leaders to Define Core Digital Measures for Alzheimer’s Disease
Cogstate has joined the Digital Medicine Society’s Alzheimer’s Disease and Related Dementias Digital Measures Development Project. Cogstate joins other DiMe partners including Biogen, Eli Lilly, Eisai, and Merck, all with the objective to define digital health measurement to speed the development of new therapies and improve AD care management.
Cogstate announced the formation of a Scientific Advisory Board (SAB), comprising clinical and scientific experts in cognitive assessment and drug development. The SAB will work closely with the Cogstate scientific leadership team to support the advancement of the company’s strategy, innovation roadmaps, and research & development initiatives.
Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Clinical Trials
Cogstate and Clario announced an expansion of their partnership to jointly provide enhanced data quality solutions for clinical trials. This collaboration broadens the companies’ previously announced partnership, which offers streamlined solutions for Cogstate digital cognitive assessments together with Clario.
Cogstate, via its global commercial partner Eisai Co., Ltd, is pleased to announce that Cogstate technology will be marketed directly to consumers in Taiwan and in Hong Kong through its Taiwanese subsidiary Eisai Taiwan Inc. (Location: Taipei) and Hong Kong subsidiary Eisai (Hong Kong) Co. This will be the first release of Cogstate technology in the Asian region (excluding Japan). Similar launch in additional countries, including Singapore, is expected shortly.
Cogstate, via its global commercial partner Eisai, is pleased to announce that Cogstate technology will be marketed in Japan as a pre-installed application on a smartphone used widely by the senior population. From February 2022, the Raku-Raku smartphone will be shipped with a version of Cogstate’s computerised assessment of cognition, called NouKNOW, pre-installed on the device.
Clinical Trial in Dementia with Lewy Bodies Used Cogstate Digital Assessments and Data Quality Services to Support the Evaluation of Neflamapimod
Cogstate announced its digital cognitive assessments were part of the primary endpoint in the AscenD-LB study, a phase 2 clinical trial in Dementia with Lewy Bodies (DLB) conducted by EIP Pharma Inc. Final study results demonstrated neflamapimod treatment led to significant improvement relative to placebo.
Cogstate is pleased to announce the appointment of two new executives who will join our Executive Leadership Team. Mr Darren Watson has been appointed as Chief Financial Officer (CFO) effective 1 February 2021 and Mr Ben Bloomfield has been appointed as Chief Technology Officer (CTO) effective 11 January 2021.
Cogstate is pleased to announce the appointment of Ms Kim Wenn as an Independent Non-Executive Director, effective immediately. Kim brings extensive technology experience and strong commercial expertise to the Board of Cogstate, with over 30 years experience in innovation roles.
Leaders from Cogstate Join the Davos Alzheimer’s Collaborative to Accelerate Innovation and Preparedness for Disease Interventions
Cogstate Ltd announced today that four members of its executive leadership team have joined the Davos Alzheimer’s Collaborative (DAC), a pre-competitive coalition and a 5-year, ~$300 million plan focused on driving global scientific, business, policy and financial coordination in Alzheimer’s disease preparedness.
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies
Eisai and Cogstate announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate for use in healthcare and other markets.
Cogstate announced the appointment of Chris Edgar, PhD as Chief Science Officer and Prof. Paul Maruff, PhD as Chief Innovation Officer. These appointments represent an expansion of the executive leadership team with strengthened scientific capacity as the company continues to meet the growing demand for transformative innovations in clinical trials and healthcare.
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Cogstate Ltd. (ASX: CGS;OTCQX: COGZF), a cognitive science and technology company publicly listed on the Australian Securities Exchange, has qualified to trade on the OTCQX® Best Market. Cogstate Ltd. upgraded to OTCQX from the Pink® market.